The purpose of this study is to compare liquid and tablet buprenorphine formulations.
Participants were inducted on either liquid or tablet buprenorphine, in a double-blind,
double-dummy manner. They each reached a steady state by the second week, and were
scheduled to have blood draws in weeks 3, 4, 7, 8, 11, 12, 15, and 16.
M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Currently enrolled in the
outpatient protocol comparing liquid and tablet formulations of Buprenorphine. Agreeable
to conditions of study and signed informed consent.
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant
and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics.
Acute hepatitis. Other medical conditions that deem participation to be unsafe.